VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS AND METHODS OF ISOLATING AND USING THE SAME

• US 20090220466A1
• Filed: 11/02/2006
• Published: 09/03/2009
• Est. Priority Date: 12/08/2005
• Status: Abandoned Application

• Current Assignee: University of Louisville
• Original Assignee: University of Louisville
• Inventors: Kucia, Magdalena, Ratajczak, Mariusz, Ratajczak, Janina
• Application Number:
  US12/096,754
• Publication Number:
  US 20090220466A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/22 Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.

Claims

1. A method of forming an embryoid body-like sphere from a population of very small embryonic-like (VSEL) stem cells or derivatives thereof, the method comprising:

(a) providing a population of CD45⁻

cells comprising VSEL stem cells or derivatives thereof; and

(b) culturing the VSEL stem cells or derivatives thereof in a medium comprising one or more factors that induce embryoid body-like sphere formation of the VSEL stem cells or derivatives thereof for a time sufficient for an embryoid body-like sphere to form.

2. The method of claim 1, wherein the VSEL stem cells or derivatives thereof comprise CD34⁺/lin⁻

/CD45⁻

or Sca-1⁺/lin⁻

/CD45⁻

very small embryonic-like (VSEL) stem cells.

3. The method of claim 1, wherein the VSEL stem cells are about 3-4 μ

m in diameter, express at least one of SSEA-1, Oct-4, Rev-1, and Nanog, posses large nuclei surrounded by a narrow rim of cytoplasm, and have open-type chromatin (euchromatin).

4. The method of claim 1, wherein the population of CD45⁻

cells comprising VSEL stem cells or derivatives thereof is isolated from a human or from a mouse.

5. The method of claim 4, wherein the population of CD45⁻

cells comprising VSEL stem cells or derivatives thereof is isolated from a source in the human or the mouse selected from the group consisting of bone marrow, peripheral blood, spleen, cord blood, and combinations thereof.

6. The method of claim 1, wherein the one or more growth factors that induce embryoid body-like sphere formation of the VSEL stem cells or derivatives thereof comprise epidermal growth factor (EGF), fibroblast growth factor-2, and combinations thereof.

7. The method of claim 1, wherein the one or more factors are provided to the VSEL stem cells or derivatives thereof by co-culturing the VSEL stem cells or derivatives thereof with C2C12 cells.

8. The method of claim 1, further comprising isolating the population of CD45⁻

cells comprising VSEL stem cells or derivatives thereof by a method comprising the steps of;

(a) providing an initial population of cells suspected of comprising CD45⁻

stem cells;

(b) contacting the initial population of cells with a first antibody that is specific for CD45 and a second antibody that is specific for CD34 or Sca-1 under conditions sufficient to allow binding of each antibody to its target, if present, on each cell of the initial population of cells;

(c) selecting a first subpopulation of cells that are CD34⁺ or Sca-1⁺, and are also CD45⁻

;

(d) contacting the first subpopulation of cells with one or more antibodies that are specific for one or more cell surface markers selected from the group consisting of CD45R/B220, Gr-1, TCRα

β

, TCRγ

δ

, CD11b, and Ter-119 under conditions sufficient to allow binding of each antibody to its target, if present, on each cell of the population of cells;

(e) removing from the first subpopulation of cells those cells that bind to at least one of the antibodies of step (d); and

(f) collecting a second subpopulation of cells that are either CD34⁺/lin⁻

/CD45⁻

or Sca-1⁺/lin⁻

/CD45⁻

, whereby a subpopulation of CD45⁻

stem cells is isolated.

9. The method of claim 8, wherein each antibody comprises a detectable label.

10. The method of claim 9, wherein the detectable label comprises a fluorescent label or a moiety that can be detected by a reagent comprising a fluorescent label.

11. The method of claim 8, wherein the separating comprises FACS sorting.

12. The method of claim 8, further comprising isolating those cells that are c-met⁺, c-kit⁺, and/or LIF-R⁺.

13. The method of claim 8, further comprising isolating those cells that express one or more genes selected from the group consisting of SSEA-1, Oct-4, Rev-1, and Nanog.

14. The method of claim 8, wherein the population of cells comprises a bone marrow sample, a cord blood sample, or a peripheral blood sample.

15. The method of claim 14, wherein the population of cells is isolated from peripheral blood of a subject subsequent to treating the subject with an amount of a mobilizing agent sufficient to mobilize the CD45⁻

stem cells comprising VSEL stem cells from bone marrow into the peripheral blood of the subject.

16. The method of claim 15, wherein the mobilizing agent comprises at least one of granulocyte-colony stimulating factor (G-CSF) and a CXCR4 antagonist.

17. The method of claim 16, wherein the CXCR4 antagonist is a T140 peptide.

18. The method of claim 15, wherein the subject is a mouse.

19. The method of claim 8, further comprising contacting the subpopulation of stem cells with an antibody that binds to CXCR4 and isolating from the subpopulation of stem cells those cells that are CXCR4⁺.

20. The method of claim 8, further comprising isolating those cells that are CXCR4⁺ and/or AC133⁺.

21. The method of claim 8, further comprising selecting those cells that are HLA-DR⁻

, MHC class I⁻

, CD90⁻

, CD29⁻

, CD105⁻

, or combinations thereof.

22. An embryoid body-like sphere comprising a plurality of very small embryonic-like (VSEL) stem cells.

23. A cell culture comprising the embryoid body-like sphere of claim 22 in a medium comprising one or more factors that induce embryoid body-like sphere formation of the VSEL stem cells or derivatives thereof.

24. A method of differentiating a very small embryonic-like (VSEL) stem cell into a cell type of interest, the method comprising:

(a) providing an embryoid body-like sphere comprising VSEL stem cells or derivatives thereof; and

(b) culturing the embryoid body-like sphere in a culture medium comprising a differentiation-inducing amount of one or more factors that induce differentiation of the VSEL stem cells or derivatives thereof into the cell type of interest until the cell type of interest appears in the culture.

25. The method of claim 24, wherein the cell type of interest is selected from the group consisting of a neuronal cell, an endodermal cell, and a cardiomyocyte, and derivatives thereof.

26. The method of claim 25, wherein the cell type of interest is a neuronal cell or a derivative thereof.

27. The method of claim 26, wherein the neuronal cell or derivative thereof is selected from the group consisting of an oligodendrocyte, an astrocyte, a glial cell, and a neuron.

28. The method of claim 26, wherein the neuronal cell or derivative thereof expresses a marker selected from the group consisting of GFAP, nestin, β

III tubulin, Olig1, and Olig2.

29. The method of claim 26, wherein the culturing is for at least about 10 days.

30. The method of claim 26, wherein the culture medium comprises about 10 ng/ml rhEGF, about 20 ng/ml FGF-2, and about 20 ng/ml NGF.

31. The method of claim 25, wherein the cell type of interest is an endodermal cell or derivative thereof.

32. The method of claim 31, wherein the culturing comprises culturing the embryoid body-like sphere in a first culture medium comprising Activin A;

and thereafter culturing the embryoid body-like sphere in a second culture medium comprising N2 supplement-A, B27 supplement, and about 10 mM nicotinamide.

33. The method of claim 32, wherein the culturing in the first culture medium is for about 48 hours.

34. The method of claim 32, wherein the culturing in the second culture medium is for at least about 12 days.

35. The method of claim 32, wherein the endodermal cell or derivative thereof expresses a marker selected from the group consisting of Nkx 6.1, Pdx 1, and C-peptide.

36. The method of claim 25, wherein the cell type of interest is a cardiomyocyte or a derivative thereof.

37. The method of claim 36, wherein the culturing is for at least about 15 days.

38. The method of claim 36, wherein the culture medium comprises a combination of basic fibroblast growth factor, vascular endothelial growth factor, and transforming growth factor β

1 in an amount sufficient to cause a subset of the embryoid body-like sphere cells to differentiate into cardiomyocytes.

39. The method of claim 36, wherein the cardiomyocyte or derivative thereof expresses a marker selected from the group consisting of Nsx2.5/Csx and GATA-4.

40. The method of claim 24, wherein the embryoid body-like sphere is prepared by:

(a) providing a population of CD45⁻

cells comprising VSEL stem cells; and

(b) culturing the VSEL stem cells in a culture medium comprising one or more factors that induce embryoid body-like sphere formation of the VSEL cells for a time sufficient for an embryoid body-like sphere to appear.

41. A formulation comprising the differentiated very small embryonic-like (VSEL) stem cell of claim 24 in a pharmaceutically acceptable carrier or excipient.

42. The formulation of claim 41, wherein the pharmaceutically acceptable carrier or excipient is acceptable for use in humans.

43. A method of treating an injury to a tissue in a subject, the method comprising administering to the subject a composition comprising a plurality of isolated CD45⁻

stem cells comprising VSEL stem cells in a pharmaceutically acceptable carrier, in an amount and via a route sufficient to allow at least a fraction of the population of CD45⁻

stem cells to engraft the tissue and differentiate therein, whereby the injury is treated.

44. The method of claim 43, wherein the injury is selected from the group consisting of an ischemic injury, a myocardial infarction, and stroke.

45. The method of claim 43, wherein the subject is a mammal.

46. The method of claim 45, wherein the mammal is selected from the group consisting of a human and a mouse.

47. The method of claim 43, wherein the isolated CD45⁻

stem cells comprising VSEL stem cells were isolated from a source selected from the group consisting of bone marrow, peripheral blood, spleen, cord blood, and combinations thereof.

48. The method of claim 43, further comprising differentiating the isolated CD45⁻

stem cells to produce a pre-determined cell type prior to administering the composition to the subject.

49. The method of claim 48, wherein the pre-determined cell type is selected from the group consisting of a neural cell, an endoderm cell, a cardiomyocyte, and derivatives thereof.

50. A method of producing a chimeric animal, the method comprising adding one or more of a population of CD45⁻

stem cells comprising VSEL stem cells to an embryo such that the one or more of the CD45⁻

stem cells develop into one or more cell types of the embryo.

51. The method of claim 50, wherein the adding comprises injecting the one or more CD45⁻

stem cells into the blastocoel of a blastocyst stage embryo.

52. The method of claim 50, wherein the adding comprises aggregating the one or more CD45⁻

stem cells comprising the VSEL stem cells with a morula stage embryo.

53. The method of claim 50, further comprising gestating the embryo after adding the one or more CD45⁻

stem cells comprising the VSEL stem cells at least until birth to provide a chimeric animal.

54. A method of purifying a very small embryonic-like (VSEL) stem cell for a cell type of interest from a population of CD45⁻

stem cells, the method comprising;

(a) providing a population of CD45⁻

stem cells comprising VSEL stem cells;

(b) identifying a subpopulation of the CD45⁻

stem cells that express a marker of VSEL stem cells; and

(c) purifying the subpopulation.

55. The method of claim 55, wherein the population and the subpopulation are both CD34⁺/CXCR4⁺/lin⁻

or Sca-1⁺/lin⁻

in addition to being CD45⁻

.

56. The method of claim 55, wherein the population of CD45⁻

stem cells comprising VSEL stem cells was isolated from a source selected from the group consisting of bone marrow, peripheral blood, spleen, cord blood, and combinations thereof.

57. The method of claim 55, wherein the cell type of interest is selected from the group consisting of a skeletal muscle cell, an intestinal epithelium cell, a pancreas cell, an endothelial cell, an epidermis cell, a melanocyte, a neuronal cell, a myocardial cell, a chondrocyte, an adipocyte, a liver cell, a pancreas cell, an endothelial cell, an epithelial cell, a retinal pigment cell, and an endodermal cell.

59. The method of claim 55, wherein the cell type of interest is a myocardial cell and the marker is selected from the group consisting of Nkx2.5/Csx, GATA-4, and MEF2C.

60. The method of claim 55, wherein the cell type of interest is an endothelial cell and the marker is selected from the group consisting of VEGFR2, VE-cadherin, von Willebrand factor, and TIE2.

61. The method of claim 55, wherein the cell type of interest is a skeletal muscle cell and the marker is selected from the group consisting of Myf5, MyoD, and myogenin.

62. The method of claim 55, wherein the cell type of interest is a liver cell and the marker is selected from the group consisting of α

-fetoprotein and CK19.

63. The method of claim 55, wherein the cell type of interest is a neural cell and the marker is selected from the group consisting of β

III tubulin, Olig1, Olig2, GFAP, and nestin.

64. The method of claim 55, wherein the cell type of interest is a pancreas cell and the marker is selected from the group consisting of Nkx 6.1 and Pdx 1.

65. The method of claim 55, wherein the cell type of interest is a melanocyte and the marker is selected from the group consisting of DCT, TYR, and TRP.

58. The method of claim 58, wherein the marker is selected from the group consisting of GFAP, Nestin, β

III tubulin, Olig1, Olig2, Myf5, MyoD, Myogenin, Nsx2.5/Csx, GATA-4, α

-Fetoprotein, CK19, Nkx 2-3, Tcf4, Nkx 6.1, Pdx 1, VE-cadherin, Krt 2-5, Krt 2-6a, BNC, DCT, TYR, and TRP.

66. A method of identifying an inducer of embryoid body-like sphere formation, the method comprising:

(a) preparing a cDNA library comprising a plurality of cDNA clones from a cell known to comprise the inducer;

(b) transforming a plurality of cells that do not comprise the inducer with the cDNA library;

(c) culturing a plurality VSEL stem cells or derivatives thereof in the presence of the transformed plurality of cells under conditions sufficient to cause the VSEL stem cells or derivatives thereof to form an embryoid body-like sphere;

(d) isolating the transformed cell comprising the inducer;

(e) recovering a cDNA clone from the transformed cell; and

(f) identifying a polypeptide encoded by the cDNA clone recovered, whereby an inducer of embryoid body-like sphere formation is identified.

67. The method of claim 66, wherein the cell known to comprise the inducer is a C2C12 cell.

68. The method of claim 66, wherein the plurality of cDNA clones comprise at least one primer binding site flanking at least one side of a cDNA cloning site in a cloning vector into which the cDNA clones are inserted.

69. The method of claim 68, further comprising amplifying the cDNA clone present in the transformed cell using primers that hybridize to primer sites flanking both sides of the cDNA cloning site.

70. The method of claim 66, wherein the identifying is by sequencing the cDNA clone.

71. A method of isolating a subpopulation of CD45⁻

stem cells comprising VSEL stem cells from umbilical cord blood or a fraction thereof, the method comprising;

(a) contacting the umbilical cord blood or the fraction thereof with a first antibody that is specific for CD45 and a second antibody that is specific for CD34 or Sca-1 under conditions sufficient to allow binding of each antibody to its target, if present, on each cell of the population of cells;

(b) selecting a first subpopulation of cells that are CD34⁺ or Sca-1⁺, and are also CD45⁻

;

(c) contacting the first subpopulation of cells with one or more antibodies that are specific for one or more cell surface markers selected from the group consisting of CD45R/B220, Gr-1, TCRα

β

, TCRγ

δ

, CD11b, and Ter-119 under conditions sufficient to allow binding of each antibody to its target, if present, on each cell of the population of cells;

(d) removing from the first subpopulation of cells those cells that bind to at least one of the antibodies of step (d); and

(e) collecting a second subpopulation of cells that are either CD34⁺/lin⁻

/CD45⁻

or Sca-1⁺/lin⁻

/CD45⁻

, whereby a subpopulation of CD45⁻

stem cells comprising VSEL stem cells is isolated.

72. The method of claim 71, further comprising incubating the umbilical cord blood or the fraction thereof or any of the subpopulations in a hypotonic solution for a time sufficient to lyse essentially all erythrocytes that might be present.

73. The method of claim 71, further comprising isolating those cells that are positive for at least one of CXCR4, c-met, c-kit, or LIF-R.